PROM1 and glioblastoma: Kim et al. (2018) developed angiopep-2 (An2) and anti-CD133 monoclonal antibody (CD133 mAb) conjugated liposomes, which could be used to deliver temozolomide for the treatment of glioblastoma multiforme (Figure 2B) (Moreira et al., 2002).